Bristol-Myers Squibb (BMY) Tops Q4 EPS by 10c, offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Bristol-Myers Squibb tops Q4 expectations, reports strong anemia drug sales
February 2, 2024 7:42 AM ESTShares of Bristol-Myers Squibb (NYSE: BMY) advanced 2.5% in the market pre-open Friday after the pharmaceutical company unveiled better-than-expected earnings and revenue for the fiscal fourth quarter.
Notably, Bristol reported Q4 earnings per share (EPS) of $1.70, ahead of Wall Streets consensus of $1.60. Revenue stood at $11.48 billion in the... More
